{"id":2258,"date":"2011-03-01T16:35:00","date_gmt":"2011-03-01T21:35:00","guid":{"rendered":"https:\/\/med.sites.unc.edu\/msi\/research\/cancer-researc\/burkitt-lymphoma\/"},"modified":"2018-04-24T09:09:46","modified_gmt":"2018-04-24T13:09:46","slug":"burkitt-lymphoma","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/msi\/research\/cancer-researc\/burkitt-lymphoma\/","title":{"rendered":"Burkitt Lymphoma"},"content":{"rendered":"<div>\n<p><img loading=\"lazy\" decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.med.unc.edu\/msi\/wp-content\/uploads\/sites\/657\/2018\/04\/export-5.png\" alt=\"\" width=\"502\" height=\"376\" \/><\/p>\n<p>Burkitt lymphoma (BL) is the most common pediatric cancer in sub-Saharan Africa and is associated with Epstein-Barr Virus (EBV). In a proof of principle study, we demonstrated increased EBV viral particles in tumor biopsies after the first dose of cyclophosphamide, suggesting that the virus had converted to a lytic infection. During the lytic cycle, EBV expresses proteins that make it susceptible to antiviral therapy. In a phase I study of pediatric patients with Burkitt lymphoma, we found that combination therapy with CPM and valacyclovir had a comparable safety profile to CPM monotherapy in children with endemic Burkitt lymphoma. We recommend that the valacyclovir recommended Phase II dose be 30 mg\/kg, 3 times daily. We are currently seeking funding for this phase II trial.<\/p>\n<p><strong>Publications<\/strong><\/p>\n<p>D Olson, ML Gulley, W Tang, C Wokocha, O Mechanic, SH Gold, N Nguluwe, C Mwansambo, C Shores (2013). Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi. Clinical Lymphoma, Myeloma, and Leukemia, 13(2):112-118.<\/p>\n<p>W Tang, P Harmon, ML Gulley, C Mwansambo, PN Kazembe, F Martinson, C Wokocha, SC Kenney, I Hoffman, C Sigel, S Maygarden, M Hoffman, C Shores (2010). Viral response to chemotherapy in endemic Burkitt lymphoma. Clinical Cancer Research, 16(7):2055-2064.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Burkitt lymphoma (BL) is the most common pediatric cancer in sub-Saharan Africa and is associated with Epstein-Barr Virus (EBV). In a proof of principle study, we demonstrated increased EBV viral particles in tumor biopsies after the first dose of cyclophosphamide, suggesting that the virus had converted to a lytic infection. During the lytic cycle, EBV &hellip; <a href=\"https:\/\/www.med.unc.edu\/msi\/research\/cancer-researc\/burkitt-lymphoma\/\" aria-label=\"Read more about Burkitt Lymphoma\">Read more<\/a><\/p>\n","protected":false},"author":12057,"featured_media":0,"parent":2238,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-2258","page","type-page","status-publish","hentry","odd"],"acf":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/msi\/wp-json\/wp\/v2\/pages\/2258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/msi\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/msi\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/msi\/wp-json\/wp\/v2\/users\/12057"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/msi\/wp-json\/wp\/v2\/comments?post=2258"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/msi\/wp-json\/wp\/v2\/pages\/2258\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/msi\/wp-json\/wp\/v2\/pages\/2238"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/msi\/wp-json\/wp\/v2\/media?parent=2258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}